Sign up

Decheng Capital LLC

$731.7M assets · 14 holdings · Q2 2026 · Filed 14 AUG 2026

About Decheng Capital LLC’s 13F portfolio

Decheng Capital LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Decheng Capital LLC reported $731.7M across 14 US-listed positions (). Its largest position is CG ONCOLOGY INC (CGON) at 62% of the reported book, and its ten biggest holdings make up 98% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$731.7M
Assets (13F)
#2,906
of 8,839 by size
14
Holdings
98%
Top-10 weight
1
Buys
4
Sells
Top holdings · Q2 2026
14 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: CGON
CG ONCOLOGY INC
$80.00
+1.34%
62%
6.4M$452.7M
2
NYSE: NUVB
Nuvation Bio Inc.
$3.78
−3.08%
20%
26.0M$147.4M
3
NASDAQ: AARD
AARDVARK THERAPEUTICS INC
$0.91
−20.87%
3.1%
3.9M$22.6M
4
NASDAQ: ACRS
Aclaris Therapeutics, Inc.
$3.50
+3.55%
2.9%
4.0M$21.4M
5
NASDAQ: UPB
Upstream Bio Inc.
$2.08
−0.95%
2.6%
2.7M$18.9M
6
NYSE: RCUS
Arcus Biosciences, Inc
$15.76
−3.84%
2.0%
465K$14.3M
7
NASDAQ: EQ
Equillium Inc.
$1.10
−9.09%
1.9%
4.4M$14.2M
8
NASDAQ: RVMD
REVOLUTION MEDICINES INC(NSM)
$159.82
−1.76%
1.3%
53K$9.9M
9
NASDAQ: LYEL
Lyell Immunopharma, Inc.
$13.89
+1.61%
1.3%
692K$9.7M
10
NASDAQ: BYSI
BeyondSpring Inc.
$0.45
−19.09%
0.9%
3.8M$6.7M
11
NASDAQ: ZNTL
Zentalis Pharmaceuticals Inc.
$1.36
−8.72%
0.9%
1.3M$6.4M
12
NASDAQ: NAMS
NEWAMSTERDAM PHARMA CO NV
$19.74
+1.81%
0.8%
177K$6.0M
13
NASDAQ: PYXS
Pyxis Oncology, Inc (formerly Apexigen)
$1.41
−2.08%
0.1%
327K$984K
14
NASDAQ: TNGX
TANGO THERAPEUTICS INC
$21.89
−1.00%
0.1%
20K$625K

Showing the 14 largest positions reported in this 13F.

Sector allocation
  • Healthcare100%
Recent activity · vs 2026-03-31
Bought1
  • NewTNGXTANGO THERAPEUTICS INC—$625K
Sold4
  • ReducedRCUSArcus Biosciences, Inc−2.7%$14.3M
  • ReducedRVMDREVOLUTION MEDICINES INC(NSM)−43.7%$9.9M
  • ReducedNAMSNEWAMSTERDAM PHARMA CO NV−45.6%$6.0M
  • SoldKRYSKRYSTAL BIOTECH INC−100%—

Reading Decheng Capital LLC’s 13F portfolio

Decheng Capital LLC’s $731.7M 13F book is spread across 14 reported positions and is highly concentrated — its ten largest positions alone are 98% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are CGON, NUVB, AARD, ACRS and UPB, led by CG ONCOLOGY INC (CGON) at 62% of the portfolio. The heaviest sector exposure is Healthcare (100%).

What Decheng Capital LLC changed last quarter

Between 2026-03-31 and Q2 2026, Decheng Capital LLC was a net seller: it opened 1 new positions and added to 0 more, while trimming 3 and closing 1 outright. Against a 14-name book, that is moderate turnover, pointing to steady rotation within the portfolio. Its largest new or increased position was TANGO THERAPEUTICS INC (TNGX), and its biggest reduction was Arcus Biosciences, Inc (RCUS).

What a 13F does and doesn’t reveal

A 13F captures only Decheng Capital LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Decheng Capital LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Decheng Capital LLC's profile on this page is built directly from those filings.

How current is the 13F data on Decheng Capital LLC's page?

It reflects Decheng Capital LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Decheng Capital LLC files its next quarterly report, this page refreshes automatically.

Can I see Decheng Capital LLC's complete list of holdings?

This page highlights Decheng Capital LLC's largest positions rather than all 14 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Decheng Capital LLC's filings.

Does a 13F show everything Decheng Capital LLC owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Decheng Capital LLC's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Decheng Capital LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.